Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BORIS Double Nickase Plasmid (h): sc-403313-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BORIS Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- BORIS Double Nickase Plasmid (h) and BORIS Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CTCFL. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BORIS Antibody (F-1): sc-377085
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BORIS Double Nickase Plasmid (h) | sc-403313-NIC | 20 µg | $410.00 | |||
BORIS Double Nickase Plasmid (h2) | sc-403313-NIC-2 | 20 µg | $410.00 |
CTCFL encodes BORIS (Brother of the Regulator of Imprinted Sites), a cancer-testis transcriptional regulator related to CTCF that binds DNA in a sequence-specific manner to influence chromatin organization and gene expression programs. BORIS participates in epigenetic regulation, including imprinting control and modulation of chromatin accessibility, and can intersect with processes such as transcriptional insulation, enhancer–promoter communication, and germline-associated transcriptional networks. Aberrant BORIS expression has been reported in diverse tumor contexts and is frequently studied for its links to dysregulated epigenetic states, altered transcriptional circuitry, and genome stability phenotypes. As a human gene with restricted normal tissue expression, CTCFL is a useful model for investigating mechanisms of chromatin-dependent transcriptional control and oncogenic reprogramming.
BORIS Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CTCFL locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CTCFL. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CTCFL function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CTCFL-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.